LataMed AI Corp. (OTC: LMEDD) announced that its 5-for-1 forward stock split became effective at market open on July 15, 2026, following publication on the FINRA Daily List. The forward split, combined with a mandatory share exchange and new CUSIP number (21116R404), is designed to increase the number of outstanding shares and potentially improve trading liquidity. The temporary trading symbol LMEDD will be used for approximately 20 business days before reverting to LMED.
This corporate action is significant for LataMed AI as it aligns with the company's broader strategy to advance its digital health and artificial intelligence platforms, including CardioAI, PulmoAI, and NeuroAI. Dr. Kevin Rodan Levy, CEO, stated that the forward split represents an important milestone and that the company is focused on expanding its telemedicine platform and pursuing commercialization opportunities. The move is expected to make shares more accessible to investors, potentially boosting market activity and supporting future capital-raising efforts.
The forward stock split does not require any action from shareholders holding shares through brokerage accounts or in book-entry form, as the adjustment will be processed automatically. For shareholders with physical certificates, no immediate action is needed, but certificates presented for transfer or sale will be exchanged under the new CUSIP. The company's transfer agent will handle these exchanges in accordance with mandatory exchange procedures.
LataMed AI, a development-stage company, targets emerging markets, particularly Latin America, with its telehealth infrastructure and AI-enabled healthcare solutions. The forward split may signal management's confidence in its growth trajectory, as it often precedes efforts to attract a broader investor base or meet exchange listing requirements. However, the company remains subject to risks typical of development-stage enterprises, including regulatory hurdles and technology deployment challenges.
Investors should note that the forward split does not change the company's fundamental valuation but can affect per-share price and liquidity. LataMed AI encourages shareholders to consult their brokerage firms or the company's transfer agent for questions. For more information, visit https://latamed.ai or review SEC filings at www.sec.gov.
This announcement underscores LataMed AI's commitment to its long-term strategy, focusing on AI-driven healthcare solutions in underserved regions. The successful implementation of the forward split may pave the way for enhanced market visibility and investor engagement as the company pursues commercialization milestones.
